Crispr Therapeutics AG (OQ:CRSP)

Business Focus: Biotechnology & Medical Research

Mar 13, 2024 08:30 am ET
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Christian Rommel, Ph.D., to its Board of Directors at the Company’s...
Feb 21, 2024 07:30 am ET
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
— CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain — — Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70, respectively —  —...
Feb 15, 2024 08:30 am ET
CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Citi 2024 Virtual Oncology...
Feb 13, 2024 08:30 am ET
CRISPR Therapeutics Announces $280 Million Registered Direct Offering
Led by new investor EcoR1 Capital and SR One with participation from existing and new investors - - Well positioned to execute on our on-going clinical trials in oncology, cardiovascular and diabetes, and further accelerate our auto-immune and in...
Feb 13, 2024 02:30 am ET
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced today that the European Commission has granted conditional marketing authorization to CASGEVY™...
Jan 16, 2024 04:01 pm ET
CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene...
Jan 08, 2024 07:00 am ET
CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and 2024 outlook as the Company enters its next phase of...
Jan 04, 2024 08:31 am ET
Thinking about trading options or stock in MINISO Group, Advanced Micro Devices, Crispr Therapeutics, Arista Networks, or ZIM Integrated Shipping Services?
NEW YORK, Jan. 4, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MNSO, AMD, CRSP, ANET, and ZIM.
Jan 03, 2024 08:30 am ET
CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 42nd Annual J.P. Morgan...
Dec 12, 2023 08:31 am ET
Thinking about buying stock in Crispr Therapeutics, Ardelyx, ADC Therapeutics, Acurx Pharmaceuticals, or Sphere 3D?
NEW YORK, Dec. 12, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRSP, ARDX, ADCT, ACXP, and ANY.
Dec 08, 2023 12:52 pm ET
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 genome-edited cell therapy, for the treatment of sickle cell disease (SCD) in patients 12 years and older w
Dec 04, 2023 04:15 pm ET
CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today provided an update on its immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric...
Nov 16, 2023 08:31 am ET
Thinking about trading options or stock in Palantir Technologies, SoFi Technologies, Broadcom, Truist Financial, or Crispr Therapeutics?
NEW YORK, Nov. 16, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLTR, SOFI, AVGO, TFC, and CRSP.
Nov 16, 2023 01:45 am ET
 Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Di
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for th
Nov 06, 2023 04:15 pm ET
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
Clinical trials ongoing for our CAR T product candidates, CTX110® and CTX112™, targeting CD19 in B-cell malignancies- -Clinical trials ongoing for our CAR T product candidates, CTX130™ and CTX131™, targeting CD70 in T cell malignancies and solid...
Nov 06, 2023 08:31 am ET
Thinking about trading options or stock in Ford Motor, Palantir Technologies, Crispr Therapeutics, NVIDIA, or Fortinet?
NEW YORK, Nov. 6, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for F, PLTR, CRSP, NVDA, and FTNT.
Nov 06, 2023 05:01 am ET
CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced preclinical data from the Company’s investigational programs for the treatment of...
Oct 31, 2023 05:53 pm ET
CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease
ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee meeting for...
Oct 31, 2023 07:05 am ET
CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that NASDAQ has halted trading of the Company’s common stock. The U.S. Food and Drug...
Oct 16, 2023 08:00 am ET
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Sandy Mahatme, LL.M. to its Board of Directors at the Company’s next...
Sep 27, 2023 09:01 am ET
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced poster presentations of preclinical data at the Society for Immunotherapy of Cancer (SITC)...
Sep 07, 2023 08:30 am ET
CRISPR Therapeutics Announces Leadership Transition
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Rodger Novak, M.D., President and Chairman of the Board of CRISPR Therapeutics, has...
Aug 30, 2023 08:00 am ET
CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat...
Aug 07, 2023 04:01 pm ET
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
Continues to advance its lead in vivo program, CTX310™, targeting angiopoietin-related protein 3 (ANGPTL3), into the clinic this year- ZUG, Switzerland and BOSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a...
Jun 13, 2023 09:00 am ET
CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat...
Jun 09, 2023 03:01 am ET
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that both pivotal trials for exagamglogene autotemcel (exa-cel) in patients with transfusion-dependent beta thalassemia (TDT) or severe sickle cell disease (SCD) met primary and key secondary endpoints at pre-specified interim anal
Jun 08, 2023 07:23 pm ET
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Applications (BLAs) for the investigational treatment exagamglogene autotemcel (exa-cel) for severe sickle cell disease (SCD) and transfusion-depen
May 08, 2023 04:01 pm ET
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
EU and U.K. submissions validated by European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA); exa-cel has been granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from...
May 02, 2023 08:00 am ET
CRISPR Therapeutics to Participate Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in fireside chats...
Apr 13, 2023 04:01 pm ET
CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat...
Apr 03, 2023 08:00 am ET
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Th
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the rolling Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for the investigational treatment exagamglogene autotemcel (exa-cel) for sickle cell disease (SCD) and transfusion-d
Mar 29, 2023 08:00 am ET
CRISPR Therapeutics Announces Departure of Board Member
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Brad Bolzon, Ph.D., Chairman and Managing Director of Versant Ventures, is stepping...
Mar 27, 2023 08:00 am ET
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1
Mar 14, 2023 06:02 pm ET
CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation of preclinical data at the American Association for Cancer Research...
Mar 13, 2023 04:15 pm ET
CRISPR Therapeutics Announces Transition of Chief Financial Officer
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the hiring and appointment of Raju Prasad, Ph.D., as Chief Financial Officer, effective March...
Feb 27, 2023 08:00 am ET
CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat...
Feb 21, 2023 04:01 pm ET
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Expects to advance its lead in vivo program, CTX310™, targeting angiopoietin-related protein 3 (ANGPTL3) into clinical trials this year- ZUG, Switzerland and BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a...
Feb 08, 2023 08:00 am ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in fireside chats...
Jan 11, 2023 08:00 am ET
CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in B. Riley...
Dec 19, 2022 08:30 am ET
CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Alex Harding, M.D., M.B.A., as Senior Vice President and Head of...
Dec 12, 2022 10:00 am ET
CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today provided an update for both Part A and Part B of the Company’s ongoing Phase 1 CARBON trial...
Dec 10, 2022 08:00 am ET
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced an oral, encore presentation of clinical data from patients with sickle cell disease (SCD) or transfusion-dependent beta-thalassemia (TDT) treated with the investigational therapy exagamglogene autotemcel (exa-cel) in CLIMB-111 or
Dec 01, 2022 08:00 am ET
CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat...
Nov 10, 2022 05:40 pm ET
CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today presented data for CTX130™ for the treatment of relapsed or refractory renal cell carcinoma (RCC) as...
Nov 03, 2022 09:06 am ET
CRISPR Therapeutics Announces Poster Presentation on CTX110® at the American Society of Hematology (ASH) 2022 Annual Meeting
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a poster on CTX110®, its wholly-owned allogeneic CAR-T cell...
Nov 01, 2022 04:01 pm ET
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
ZUG, Switzerland and BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the...
Oct 27, 2022 08:30 am ET
CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Lawrence Klein, Ph.D., will be stepping down from the...
Oct 05, 2022 08:05 am ET
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation and a poster presentation at the Society for Immunotherapy of Cancer...
Sep 29, 2022 08:00 am ET
CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the BMO...
Sep 28, 2022 08:00 am ET
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced...
Aug 31, 2022 08:00 am ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following...
Aug 08, 2022 08:00 am ET
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the second quarter ended June 30, 2022. “Strong progress continues...
Jun 11, 2022 11:00 am ET
CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today presented positive results from the Company’s ongoing Phase 1 COBALT™-LYM trial evaluating the...
Jun 08, 2022 08:00 am ET
CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Goldman...
Jun 02, 2022 10:05 am ET
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) today announced new late-breaking clinical data accepted for oral presentation at the 2022 European Hematology Association (EHA) Congress. Vertex also announced three abstracts accepted for poster presentation at EHA.
May 31, 2022 08:00 am ET
CRISPR Therapeutics to Host Innovation Day on June 21, 2022
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will host an Innovation Day focused on early research and development on Tuesday,...
May 16, 2022 04:01 pm ET
CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D., FACP, as Chief Medical Officer,...
May 12, 2022 10:33 am ET
CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA)
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that an abstract providing safety and efficacy data from the ongoing CTX130™ clinical...
May 09, 2022 04:01 pm ET
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the first quarter ended March 31, 2022. “I am pleased with the...
May 04, 2022 08:00 am ET
CRISPR Therapeutics to Present at the 2022 Bank of America Healthcare Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the 2022 Bank...
Apr 12, 2022 04:01 pm ET
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Maria Fardis, Ph.D., MBA, to its Board of Directors at the Company’s...
Apr 07, 2022 04:01 pm ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following...
Mar 08, 2022 04:35 pm ET
CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2022 Annual Meeting
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present an e-poster at the American Association for Cancer Research (AACR)...
Feb 28, 2022 08:00 am ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following...
Feb 15, 2022 04:01 pm ET
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results...
Feb 09, 2022 08:00 am ET
CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the 11th Annual...
Feb 02, 2022 08:30 am ET
CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement...
Nov 23, 2021 08:30 am ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following...
Nov 22, 2021 08:30 am ET
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced...
Nov 16, 2021 08:30 am ET
CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement...
Nov 03, 2021 04:01 pm ET
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the third quarter ended September 30, 2021. “The third quarter...
Nov 02, 2021 08:00 am ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following...
Oct 14, 2021 07:00 am ET
CRISPR Therapeutics Announces Transition of Chief Financial Officer
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Brendan Smith as Chief Financial Officer, effective today. Mr. Smith...
Oct 12, 2021 04:01 pm ET
CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies
Expanding CARBON into a potentially registrational trial in 1Q 2022- -Management to host webcast and conference call today at 4:30 PM ET- ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:...
Oct 05, 2021 04:05 pm ET
CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that management will host a virtual event on October 12, 2021 at 4:30 p.m. ET to highlight...
Oct 01, 2021 08:00 am ET
CRISPR Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced two poster presentations at the Society for Immunotherapy of Cancer (SITC) 36th Annual...
Sep 28, 2021 08:00 am ET
CRISPR Therapeutics to Participate in the Chardan’s 5th Annual Genetic Medicines Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Chardan’s...
Aug 05, 2021 08:00 am ET
CRISPR Therapeutics to Participate in the Canaccord Genuity 41st Annual Growth Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Canaccord...
Jul 30, 2021 09:31 am ET
Thinking about trading options or stock in Atlassian, Crispr Therapeutics, Qiagen, Apple, or Pfizer?
NEW YORK, July 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TEAM, CRSP, QGEN, AAPL, and PFE.
Jul 29, 2021 04:30 pm ET
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the second quarter ended June 30, 2021. “We concluded an important...
Jun 28, 2021 09:31 am ET
Thinking about trading options or stock in Beam Therapeutics, Crispr Therapeutics, Tesla, AMC Entertainment, or Regeneron Pharmaceuticals?
NEW YORK, June 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BEAM, CRSP, TSLA, AMC, and REGN.
Jun 15, 2021 07:15 am ET
CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia  
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and Capsida Biotherapeutics Inc., a biotechnology company dedicated to developing breakthrough gene...
Jun 11, 2021 09:31 am ET
Thinking about trading options or stock in Crispr Therapeutics, AMC, Atomera, Prothena Corp, or Eli Lilly?
NEW YORK, June 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRSP, AMC, ATOM, PRTA, and LLY.
May 25, 2021 08:00 am ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following...
May 12, 2021 11:00 am ET
Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virt
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced two abstracts detailing updated data from the ongoing CTX001 clinical trials have been accepted for presentation during the European...
May 06, 2021 04:01 pm ET
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
Nkarta obtains a license to CRISPR gene editing technology for use in its own engineered NK cell therapy products- -Nkarta to host conference call today at 4:30 p.m. ET- ZUG, Switzerland, CAMBRIDGE, Mass., and SOUTH SAN FRANCISCO, Calif., May 06,...
Apr 29, 2021 08:30 am ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following...
Apr 28, 2021 04:01 pm ET
CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncology Annual Meeting
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a Trials in Progress poster presentation at the American Society of...
Apr 27, 2021 04:01 pm ET
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
More than 30 patients have been dosed with CTX001 across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021- -Enrollment ongoing in CTX110™, CTX120™ and CTX130™ clinical trials- ZUG, Switzerland...
Apr 26, 2021 08:30 am ET
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo...
Apr 20, 2021 07:15 am ET
Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) today announced that the companies have amended their collaboration agreement to develop, manufacture and commercialize CTX001, an investigational...
Apr 10, 2021 08:31 am ET
CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced preclinical data from the Company’s allogeneic chimeric antigen receptor T cell (CAR-T)...
Apr 06, 2021 08:00 am ET
CRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the 20th Annual...
Mar 10, 2021 05:03 pm ET
CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a poster at the American Association for Cancer Research (AACR)...
Mar 03, 2021 08:00 am ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following...
Feb 16, 2021 04:01 pm ET
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020. “2020 was...
Feb 05, 2021 08:00 am ET
CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Guggenheim...
Feb 01, 2021 08:00 am ET
CRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Philippe Drouet as Chief Commercial Officer. Mr. Drouet brings more...
Jan 15, 2021 08:31 am ET
Thinking about trading options or stock in Axon Enterprise, Tilray, Pfizer, Crispr Therapeutics, or General Motors?
NEW YORK, Jan. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAXN, TLRY, PFE, CRSP, and GM.
Dec 28, 2020 08:31 am ET
Thinking about trading options or stock in Crispr Therapeutics, GameStop, Moderna, Tesla, or FuelCell Energy?
NEW YORK, Dec. 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRSP, GME, MRNA, TSLA, and FCEL.
Dec 22, 2020 08:31 am ET
Thinking about trading options or stock in General Electric, Plug Power, Crispr Therapeutics, Vista Outdoor, or Walt Disney?
NEW YORK, Dec. 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GE, PLUG, CRSP, VSTO, and DIS.
Dec 14, 2020 08:00 am ET
CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the receipt of a grant from the Bill & Melinda Gates Foundation to research in vivo gene...
Dec 05, 2020 12:30 pm ET
CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication
CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new data on a total of 10 patients treated with the investigational CRISPR/Cas9-based gene-editing therapy, CTX001, that show a consistent and...
Dec 01, 2020 09:00 am ET
CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Edi
CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the companies will host an investor webcast on December 9, 2020 at 8:00 a.m. ET to review clinical data presented during the Plenary...
Nov 24, 2020 08:00 am ET
CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Piper...
Nov 16, 2020 08:00 am ET
CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the...
Nov 04, 2020 09:15 am ET
CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition
CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data in seven patients from two ongoing Phase 1/2 clinical trials of the investigational CRISPR/Cas9 gene-editing therapy CTX001 in severe...
Oct 28, 2020 08:00 am ET
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results
Received Orphan Drug Designation (ODD) for Phase 1 clinical trial of CTX120™, targeting B-cell maturation antigen (BCMA)- -Began treating patients in two Phase 1 clinical trials of CTX130™, targeting CD70 for the treatment of both solid tumors...
Oct 21, 2020 07:00 am ET
CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced positive top-line results from the Company’s ongoing Phase 1 CARBON trial evaluating the...
Oct 07, 2020 09:25 am ET
CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry
CRISPR Therapeutics (Nasdaq: CRSP), today announced Professor Emmanuelle Charpentier, CRISPR Therapeutics’ co-founder, has been awarded the 2020 Nobel Prize in Chemistry for her groundbreaking work on the CRISPR/Cas9 system. Professor Charpentier...
Sep 29, 2020 08:00 am ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the...
Sep 22, 2020 09:00 am ET
CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease
CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo...
Sep 03, 2020 08:00 am ET
CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled...
Jul 30, 2020 08:00 am ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the...
Jul 27, 2020 04:30 pm ET
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results
Expands regenerative medicine portfolio through a collaboration with University Health Network (UHN), gaining access to hepatocytes- ZUG, Switzerland and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP),...
Jun 30, 2020 09:30 pm ET
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 6,428,572 common shares at a public...
Jun 29, 2020 04:01 pm ET
CRISPR Therapeutics Announces Proposed Offering of Common Shares
CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of $325,000,000 of common shares....
Jun 25, 2020 08:00 am ET
CRISPR Therapeutics Announces the Build-Out of New Cell Therapy Manufacturing Facility
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it is building a new cell therapy manufacturing facility in Framingham, Massachusetts...
Jun 12, 2020 02:30 am ET
CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congres
CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new clinical data for CTX001, an investigational CRISPR/Cas9 gene-editing therapy, from the CLIMB-111 and CLIMB-121 Phase 1/2 trials in...
May 26, 2020 08:30 am ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the...
May 15, 2020 08:30 am ET
CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that four abstracts have been accepted for poster presentation at the American Association...
May 14, 2020 09:02 am ET
New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress
CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that new data from two ongoing Phase 1/2 clinical trials of the CRISPR/Cas9 gene-editing therapy CTX001 in severe hemoglobinopathies have been...
May 11, 2020 09:00 am ET
CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies
CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX001, an...
May 07, 2020 08:00 am ET
CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled...
Apr 28, 2020 04:45 pm ET
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results
IND and CTA approved for CTX130™, wholly-owned allogeneic CAR-T cell therapy targeting CD70- -Received $25 million milestone payment from DMD/DM1 collaboration with Vertex in April 2020- ZUG, Switzerland and CAMBRIDGE, Mass., April 28, 2020...
Feb 26, 2020 04:05 pm ET
CRISPR Therapeutics Proposes Changes to the Board of Directors
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Doug Treco, Ph.D. to its Board of Directors at the Company’s upcoming...
Feb 12, 2020 04:05 pm ET
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 12, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results...
Jan 06, 2020 04:05 pm ET
CRISPR Therapeutics to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled...
Nov 27, 2019 07:00 am ET
CRISPR Therapeutics to Present at Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to make the following...
Nov 20, 2019 09:18 pm ET
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 4,250,000 common shares at a public...
Nov 19, 2019 04:14 pm ET
CRISPR Therapeutics Announces Proposed Public Offering of Common Shares
CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of 4,250,000 common shares. In...
Nov 19, 2019 07:00 am ET
CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies
CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced positive, interim data from the first two patients with severe hemoglobinopathies treated with the investigational CRISPR/Cas9 gene-editing...
Oct 28, 2019 07:00 am ET
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the third quarter ended September 30, 2019. “In 2019, we’ve...
Oct 15, 2019 07:00 am ET
CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and KSQ Therapeutics, a biotechnology company using CRISPR technology to enable the company’s powerful...
Oct 01, 2019 07:00 am ET
CRISPR Therapeutics to Present at Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to make the following...
Sep 17, 2019 07:00 am ET
CRISPR Therapeutics and ViaCyte Present Positive In Vitro Data Towards a Potential Immune-Evasive Cell Replacement Therapy for Diabetes at EASD 2019
CRISPR Therapeutics (Nasdaq: CRSP), and ViaCyte, Inc., a privately-held cell therapy company, today presented data from the Companies’ regenerative medicine program targeted towards type 1 diabetes (T1D) in an oral presentation at the 55th Annual...
Jul 31, 2019 07:01 am ET
CRISPR Therapeutics to Present at Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to make the following...
Jul 29, 2019 04:01 pm ET
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the second quarter ended June 30, 2019. “We have made...
Jul 01, 2019 04:01 pm ET
CRISPR Therapeutics Announces Oral Presentation at the 55th Annual Meeting of the European Association for the Study of Diabetes
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present an oral presentation at the 55th Annual Meeting of the European...
Jun 06, 2019 05:12 pm ET
Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the company is enhancing its gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) by expanding its collaboration with CRISPR Therapeutics and acquiring Exonics Therapeutics.
May 29, 2019 07:00 am ET
CRISPR Therapeutics to Present at Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled...
May 01, 2019 07:00 am ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following...
Apr 29, 2019 04:01 pm ET
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the first quarter ended March 31, 2019. “This past quarter, we began...
Apr 17, 2019 08:20 am ET
Analysis: Positioning to Benefit within CRISPR Therapeutics AG, SPIRIT MTA REIT, Gaia, Perceptron, Check-Cap, and Key Tronic — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CRISPR Therapeutics AG (NASDAQ:CRSP), SPIRIT MTA REIT (NYSE:SMTA),...
Apr 16, 2019 07:00 am ET
CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia
CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for the treatment of transfusion-dependent beta...
Apr 01, 2019 07:00 am ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to make the following...
Mar 06, 2019 07:00 am ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to make the following...
Feb 27, 2019 04:53 pm ET
CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2019 Annual Meeting
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of the CRISPR team will present two posters at the American Association for...
Feb 25, 2019 08:02 am ET
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018. “This...
Feb 25, 2019 08:00 am ET
CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001
CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reviewed recent progress in the clinical development programs for CTX001, an investigational, autologous, CRISPR/Cas9 gene-edited hematopoietic stem cell...
Feb 21, 2019 07:00 am ET
CRISPR Therapeutics Proposes New Members to the Board of Directors
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect John T. Greene and Katherine A. High, M.D. to its Board of Directors...
Feb 19, 2019 07:00 am ET
CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV)-based gene therapies, today...
Jan 22, 2019 07:00 am ET
CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies
CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and ProBioGen, a premier German service and technology provider, today announced a multi-year research...
Jan 04, 2019 07:00 am ET
CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease
CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for the treatment of sickle cell disease (SCD)....
Nov 21, 2018 07:00 am ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled...
Nov 13, 2018 08:45 am ET
New Research Coverage Highlights CAS Medical, Saia, Core Laboratories N.V, Perceptron, CRISPR Therapeutics AG, and IEC Electronics — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CAS Medical Systems, Inc. (NASDAQ:CASM), Saia, Inc. (NASDAQ:SAIA), Core...
Nov 09, 2018 07:00 am ET
CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology
CRISPR Therapeutics (NASDAQ:CRSP) and MaxCyte today announced the expansion of their existing relationship by entering into a non-exclusive commercial license agreement that will allow CRISPR Therapeutics to deploy MaxCyte’s Flow Electroporation®...
Nov 07, 2018 04:33 pm ET
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the third quarter ended September 30, 2018 and commented on recent...
Oct 10, 2018 04:01 pm ET
CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease
CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug...
Oct 02, 2018 07:00 am ET
CRISPR Therapeutics to Present at the Chardan Genetic Medicines Conference
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer, will present at the Chardan Genetic...
Sep 20, 2018 08:33 pm ET
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 4,210,526 common shares at a public...
Sep 19, 2018 04:08 pm ET
CRISPR Therapeutics Announces Proposed Public Offering of Common Shares
CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of $200,000,000 of its common...
Sep 17, 2018 08:00 am ET
CRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a privately held regenerative medicine company, today announced a collaboration...
Sep 10, 2018 04:30 pm ET
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Re
CRISPR Therapeutics AG (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Caribou Biosciences, Inc. announced that the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) affirmed the decision by the U.S. Patent and...
Aug 30, 2018 07:00 am ET
CRISPR Therapeutics to Present at Upcoming Investor Conferences
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to make the following...
Aug 07, 2018 05:01 pm ET
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2018 Financial Results
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today reported financial results for the second quarter 2018 and commented on recent accomplishments and...
Jun 19, 2018 09:05 am ET
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing
CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA), and Caribou Biosciences, Inc., announced that The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier, Ph.D. (collectively,...
Jun 05, 2018 08:00 am ET
CRISPR Therapeutics to Participate in Three June Conferences
CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to present at three conferences in...
May 30, 2018 04:30 pm ET
CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease
CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Investigational New Drug Application (IND) for CTX001 for the...
May 15, 2018 08:00 am ET
CRISPR Therapeutics Announces Presentations at the ASGCT 21st Annual Meeting
CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of the CRISPR team will make a series of presentations at the American Society...
May 08, 2018 08:00 am ET
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results
CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today provided a business update and announced financial results for the first quarter ended March 31,...
May 03, 2018 04:01 pm ET
CRISPR Therapeutics to Participate in May Investor Conferences
CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to present at two upcoming...
Apr 16, 2018 04:01 pm ET
CRISPR Therapeutics Presents Positive Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018
-Off-the-shelf CAR-T candidates against BCMA and CD70 address both hematologic malignancies and solid tumors -
Apr 13, 2018 08:00 am ET
CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018
ZUG, Switzerland and CAMBRIDGE, Mass., April 13, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the Company is scheduled to present new data on...
Apr 12, 2018 08:25 am ET
Market Trends Toward New Normal in Argo Group International, Methanex, Industrias Bachoco, S.A. de C.V, CRISPR Therapeutics AG, Astec Industries, and Sprague Resources LP — Emerging Consolidated Expec
NEW YORK, April 12, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Argo Group International Holdings, Ltd. (NASDAQ:AGII),...
Apr 04, 2018 04:01 pm ET
CRISPR Therapeutics Announces the Appointment of Steve Caffé as Head of Regulatory Affairs
ZUG, Switzerland and CAMBRIDGE, MA., April 04, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced the appointment of Steve Caffé, M.D., as Head of Regulatory Affairs....
Mar 26, 2018 04:01 pm ET
CRISPR Therapeutics Announces the Retirement of Tyler Dylan-Hyde and Appointment of Shelby Walker as Head of Intellectual Property
ZUG, Switzerland and CAMBRIDGE, Mass., March 26, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the retirement of Dr. Tyler Dylan-Hyde as Chief Legal Officer...
Mar 14, 2018 07:40 am ET
Analysis: Positioning to Benefit within CURO Group, Golar LNG Partners LP, CRISPR Therapeutics AG, Kinross Gold, Enerplus, and ManTech International — Research Highlights Growth, Revenue, and Consolid
NEW YORK, March 14, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CURO Group Holdings Corp. (NYSE:CURO), Golar...
Mar 08, 2018 04:15 pm ET
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results
- On track to begin first company-sponsored clinical trials of a CRISPR-based therapy -- Wholly-owned CRISPR-based allogeneic CAR-T programs advancing rapidly -
Feb 21, 2018 08:30 am ET
CRISPR Therapeutics to Participate in Four Upcoming Investor Conferences
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 21, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced that members of its senior management team are scheduled to present at four upcoming...
Feb 08, 2018 04:30 pm ET
CRISPR Therapeutics Announces Transition of Bill Lundberg, MD
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that Bill Lundberg, MD, is stepping down as Chief Scientific...
Jan 04, 2018 07:03 pm ET
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 5,000,000 of...
Jan 03, 2018 06:15 am ET
CRISPR Therapeutics Announces Proposed Public Offering of Common Shares
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of $100,000,000...
Dec 21, 2017 08:00 am ET
CRISPR Therapeutics Announces Appointment of Dr. Rodger Novak as Chairman of the Board
ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today announced the appointment of Dr. Rodger Novak, founder and former CEO of CRISPR Therapeutics as Chairman of the Board of Directors. Dr. Novak...
Dec 12, 2017 08:30 am ET
Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and β-Thalassemia
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) today announced that the companies will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as part of the companies’ previously announced collaboration aimed at the discovery and development of
Dec 10, 2017 07:45 am ET
CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Therapy for β-Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting
CRISPR gene-editing in hematopoietic stem cells demonstrates potential to treat β-thalassemia and sickle cell disease through upregulation of fetal hemoglobin
Dec 07, 2017 07:00 am ET
Dec 05, 2017 08:00 am ET
CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Medicine for β-Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting
ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today announced that Dr. Bill Lundberg, Chief Scientific Officer of CRISPR, is scheduled to present new data on CTX001, an investigational CRISPR gene-edited therapy...
Nov 28, 2017 08:00 am ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced that members of its senior management team are scheduled to...
Nov 13, 2017 08:00 am ET
CRISPR Therapeutics Announces Appointment of Michael Tomsicek as Chief Financial Officer
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the appointment of Michael Tomsicek as Chief Financial Officer. Mr. Tomsicek...
Nov 13, 2017 05:00 am ET
CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs
CureVac’s mRNA technology accessed to express Cas9 for in vivo liver-targeted therapies 
Nov 10, 2017 08:00 pm ET
CRISPR Therapeutics Highlights New Additions to Portfolio of Allogeneic CRISPR-based CAR-T Therapies at SITC Annual Meeting
- CRISPR-based CAR-T cell therapy candidates targeting CD19+, BCMA and CD70 demonstrate high editing rates, and potent anti-tumor activity in preclinical models -- Expanding applicability of CRISPR-based CAR-T therapy to solid tumors -...
Nov 10, 2017 08:00 pm ET
CRISPR Therapeutics Highlights New Additions to Portfolio of Allogeneic CRISPR-based CAR-T Therapies at SITC Annual Meeting
- CRISPR-based CAR-T cell therapy candidates targeting CD19+, BCMA and CD70 demonstrate high editing rates, and potent anti-tumor activity in preclinical models -- Expanding applicability of CRISPR-based CAR-T therapy to solid tumors -
Nov 08, 2017 04:05 pm ET
CRISPR Therapeutics Announces Third Quarter 2017 Financial Results and Provides Business Update
- On track to begin first company-sponsored clinical trial of a CRISPR-based therapeutic -- Wholly-owned CRISPR-based CAR-T programs advancing rapidly -- New collaborations enhance work in immuno-oncology and in vivo indications -- Company Presentation and Investor Event at upcoming Society for Immunotherapy in Cancer Annual Meeting -...
Nov 08, 2017 04:05 pm ET
CRISPR Therapeutics Announces Third Quarter 2017 Financial Results and Provides Business Update
- On track to begin first company-sponsored clinical trial of a CRISPR-based therapeutic -- Wholly-owned CRISPR-based CAR-T programs advancing rapidly -- New collaborations enhance work in immuno-oncology and in vivo indications -- Company Presentation and Investor Event at upcoming Society...
Nov 07, 2017 08:00 am ET
CRISPR Therapeutics to Present New Data on Allogeneic CRISPR-based CAR-T Program and Host Investor Reception at the 32nd Annual Society for Immunotherapy of Cancer Meeting
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced that the Company will present a poster on CRISPR’s Allogeneic...
Oct 04, 2017 04:01 pm ET
CRISPR Therapeutics to Present at Investor Conferences in October
ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 04, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., President of CRISPR Therapeutics, is scheduled to present at two upcoming Investor Conferences in October....
Jul 25, 2017 05:00 pm ET
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing
Appeal seeks reversal of Patent Trial and Appeal Board decision terminating interference without determining priority of inventorship of CRISPR/Cas9 gene editingBrief asserts that the Board failed to properly apply controlling U.S. Supreme Court and Federal Circuit precedents, and ignored evidence of multiple groups readily applying CRISPR/Cas9 gene editing to eukaryotic cells following teachings of Charpentier-Doudna team ZUG, Switzerland, CAMBRIDGE, Mass., BERKELEY, Calif. and DUBLIN, Ireland, July 25, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics, Inc...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.